China
· Delayed Price · Currency is CNY InventisBio Company Description
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China.
The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II clinical trial to treat various cancers, such as non-small cell lung cancer and colorectal cancer with KRASG12C mutations.
Its drug candidates for the metabolic therapeutic area is D-0120, a Phase II clinical trial product for hyperuricemia and gout indications; and D-2570, a oral selective inhibitor for the treatment of autoimmune diseases such as psoriasis.
In addition, the company offers preclinical products, including YF 087 for MSI high cancers, and YF550 for chromosome instability cancers.
InventisBio Co., Limited was founded in 2013 and is headquartered in Pudong, China.
| Country | China |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 168 |
| CEO | Yaolin Wang |
Contact Details
Address: No.4, Libing Road Pudong, 201203 China | |
| Phone | 86 21 5077 8527 |
| Website | inventisbio.com |
Stock Details
| Ticker Symbol | 688382 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yaolin Wang | Chief Executive Officer and Chairman |
| Luwei Shi | Chief Financial Officer, Chief Accountant and Director |
| Xing Dai | Deputy GM and Director |
| Zhang Ling | Deputy GM and Chief Medical Officer |
| Yueheng Jiang | Deputy GM, Secretary and Director |
| Ji Fang Weng | R and D Director and Employee Representative Supervisor |